A late-stage study reported at the European Society for Medical Oncology found that AstraZeneca's Tagrisso, currently approved as a therapy for lung cancer patients with EGFR mutations who have received other treatments first, showed positive results as a first-line treatment compared with standard-of-care tyrosine kinase inhibitors. Risk of disease progression or death was 54% lower with Tagrisso, and serious side effects were lower as well.
Tagrisso results encouraging as first-line EGFR lung cancer treatment
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.